{"favorite_id": 10016, "calc_type": "", "dosing": false, "full_title_en": "Dual Antiplatelet Therapy (DAPT) Score", "short_title_en": "DAPT Score", "medium_description_en": "<span id=\"docs-internal-guid-b2a1d016-dbee-e68c-d348-1ff720e39263\">Predicts which patients will benefit from prolonged DAPT after coronary stent placement.</span>", "short_description_en": "Prolonged (>1 year) dual antiplatelet therapy after PCI. ", "before_use": "", "instructions_en": "", "purpose_en": ["Treatment"], "disease_en": ["Acute Coronary Syndrome", "Myocardial Infarction", "Stroke/TIA", "Intracranial Hemorrhage"], "specialty_en": ["Internal Medicine", "Family Practice", "Neurology", "Cardiology", "Primary Care"], "chief_complaint_en": ["Chest Pain", "Shortness of Breath", "Bleeding"], "system_en": ["Hematologic", "Cardiac"], "search_abbreviation_en": ["DAPT Score", "bleeding risk", " ischemic risk"], "slug": "dual-antiplatelet-therapy-dapt-score", "seo": {"meta_description_en": "The DAPT Score predicts which patients will benefit from prolonged DAPT after coronary stent placement.", "keywords_en": "PCI, antiplatelet therapy"}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the&nbsp;DAPT&nbsp;Score&nbsp;and want to contribute your expertise? <a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a> our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the DAPT Score&nbsp;and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td></td>\n<td>\n<p dir=\"ltr\"><strong>-2 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>-1 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>0 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>1 point</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>2 points</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Age, years</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;75</p>\n</td>\n<td>\n<p dir=\"ltr\">65-74</p>\n</td>\n<td>\n<p dir=\"ltr\">&lt;65</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cigarette smoking*</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Diabetes mellitus</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">MI at presentation</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Prior PCI or prior MI</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Paclitaxel-eluting stent</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Stent diameter &lt;3 mm</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">CHF or LVEF &lt;30%</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Vein graft stent</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>*Smoking within 1 year prior to index procedure.<br /><span id=\"docs-internal-guid-1465c56c-dbf0-e9a0-36cd-bd50a756de2f\"></span></p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"89\" /><col width=\"133\" /><col width=\"229\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>DAPT Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Ischemia/bleeding risk*</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Recommendation**</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">-2 to 1</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">Prolonged DAPT not recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">&ge;2</p>\n</td>\n<td>\n<p dir=\"ltr\">High</p>\n</td>\n<td>\n<p dir=\"ltr\">Prolonged DAPT recommended</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">*Ischemia was defined as MI, stroke, repeat coronary revascularization, or stent thrombosis. Bleeding was defined as intracerebral bleeding, bleeding causing hemodynamic compromise requiring treatment, or bleeding requiring transfusion.</p>\n<p><span id=\"docs-internal-guid-cbbecdc4-dbf1-8792-dceb-7533f300f4f9\">**From ACC guidelines, <a href=\"http://www.onlinejacc.org/content/68/10/1082\" target=\"_blank\">Levine 2016</a>.</span></p>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://jamanetwork.com/journals/jama/fullarticle/2508253 ", "text": "Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735-49."}], "Other References": [{"href": "https://www.nejm.org/doi/full/10.1056/NEJM199309023291001 ", "text": "GUSTO investigators. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. N Engl J Med. 1993;329(10):673-82."}], "Validation": [{"href": "http://annals.org/aim/article-abstract/2631185/use-dual-antiplatelet-therapy-score-guide-treatment-duration-after-percutaneous", "text": "Piccolo R, Gargiulo G, Franzone A, et al. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med. 2017;167(1):17-25."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/27046159", "text": "Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016;67(21):2492-502."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/28982692", "text": "Yoshikawa Y, Shiomi H, Watanabe H, et al. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies. Circulation. 2018;137(6):551-562."}, {"href": "http://www.onlinejacc.org/content/69/14/1861?_ga=2.168254563.399869864.1527882860-1363800592.1527882860", "text": "Banerjee S, Angiolillo DJ, Boden WE, et al. Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2017;69(14):1861-1870."}], "Clinical Practice Guidelines": [{"href": "http://www.onlinejacc.org/content/68/10/1082 ", "text": "Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016."}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Robert W. Yeh", "qa_en": "<p dir=\"ltr\"><strong>Why did you develop the DAPT Score? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?</strong></p>\n<p dir=\"ltr\">The question of how long to continue antiplatelet therapy after coronary stent procedures has troubled physicians for many years. On one hand, continuing these medications can prevent heart attacks. On the other hand, the drugs can also lead to bleeding. We wanted to develop a tool that could help clinicians identify who were the best patients to continue long term antiplatelet medications after heart stents, and who were the patients best served by shorter durations of these medications. &nbsp;</p>\n<p dir=\"ltr\"><strong>What pearls, pitfalls and/or tips do you have for users of the DAPT Score? Do you know of cases when it has been applied, interpreted, or used inappropriately?</strong></p>\n<p dir=\"ltr\">The DAPT Score gives clinicians an opportunity to see how patients with particular characteristics fared when randomized to either 30 months or 12 months of dual antiplatelet therapy after receiving a stent. The data are based on the largest ever randomized blinded trial of antiplatelet therapy that we led at the Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute). However, although this is high quality evidence that has made its way into national guidelines, the DAPT Score is meant to be used in conjunction with clinical judgment. In addition, the score was derived in patients who were not taking long term oral anticoagulants like Coumadin and had no history of major bleeding in the past.</p>\n<p dir=\"ltr\"><strong>What recommendations do you have for doctors once they have applied the DAPT Score? Are there any adjustments or updates you would make to the score based on new data or practice changes?</strong></p>\n<p dir=\"ltr\">The DAPT Score should be used to guide antiplatelet duration in conjunction with clinical judgment and applied on an individualized basis. It is not a substitute for clinical judgment. It has been validated across a number of different populations, and continues to perform well in multiple settings in terms of separating patients with high ischemic/low bleeding risk (better served with longer durations of antiplatelet medications) from other patients with low ischemic/high bleeding risk (better served with shorter durations of antiplatelets).</p>\n<p dir=\"ltr\"><strong>How do you use the DAPT Score in your own clinical practice? Can you give an example of a scenario in which you use it?</strong></p>\n<p dir=\"ltr\">We use the DAPT Score to aid in discussions with patients and their referring physicians about the proper duration of antiplatelet therapies each day. In the office, using an app is particularly valuable for patients to see what their risks are and to give context to shared decision making around this common conundrum.</p>", "creator_info": {"about_en": "<p>Robert W. Yeh, MD, is an associate professor of medicine at Harvard Medical School. He is also director of the Richard and Susan Smith Center for Outcomes Research in Cardiology at the Beth Israel Deaconess Medical Center. Dr. Yeh\u2019s primary research interests revolve around improving the value of coronary and vascular devices and therapies in clinical practice.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-robert-w-yeh.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yeh+RW%5BAu%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Age, years", "name": "age", "options": [{"label": "\u226575", "value": -2}, {"label": "65-74", "value": -1}, {"label": "<65", "value": 0}], "conditionality": "", "show_points": true, "optional": false}, {"type": "toggle", "label_en": "Cigarette smoking", "name": "smoking", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Smoking within 1 year prior to index procedure.", "optional": false}, {"type": "toggle", "label_en": "Diabetes mellitus", "name": "dm", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "MI at presentation", "name": "mi", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Prior PCI or prior MI", "name": "priorpci", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Paclitaxel-eluting stent", "name": "stent", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Stent diameter <3 mm", "name": "stentdiameter", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "CHF or LVEF <30%", "name": "chf", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Vein graft stent", "name": "veinstent", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}], "md5": "c5f3443be64ee346f2fdce4333723b83", "related_calcs": [{"calcId": 10227, "short_title_en": "ORBIT Score for Afib", "slug": "orbit-bleeding-risk-score-atrial-fibrillation"}, {"calcId": 1785, "short_title_en": "HEMORR<sub>2</sub>HAGES Score", "slug": "hemorr2hages-score-major-bleeding-risk"}, {"calcId": 38, "short_title_en": "Framingham Risk Score (Hard Coronary Heart Disease)", "slug": "framingham-risk-score-hard-coronary-heart-disease"}]}